Dose: 3.571 mg/kg
Single Dose: 3.6 (3.571)
Frequency: 8 hourly
Route: IV
Instructions: Maintenance, per week

Dose: Unlikely to be used in this age group
Single Dose:
Frequency:
Route:
Instructions:

Fosfestrol also known as Diethylstilboestrol Diphosphate. . It is of Synthetic origin and belongs to Stilboestrol. It belongs to Oestrogen Agonist pharmacological group on the basis of mechanism of action and also classified in Sex Hormones and Antineoplastic Agent pharmacological group.The Molecular Weight of Fosfestrol is 428.30.

Fosfestrol is contraindicated in conditions like Hypertension,Cardiac failure,Liver diseases,Cerebrovascular disease.

The severe or irreversible adverse effects of Fosfestrol, which give rise to further complications include Congestive heart failure, CHF, Breast tenderness, Pulmonary embolism, Pulmonary thrombosis, CVA, Bone marrow toxicity, Mental disturbances, Breast enlargement, Testicular atrophy.Fosfestrol produces potentially life-threatening effects which include Thromboembolic cardiovascular accidents, Fluid & sodium retention. which are responsible for the discontinuation of Fosfestrol therapy.The signs and symptoms that are produced after the acute overdosage of Fosfestrol include Fluid retension.The symptomatic adverse reactions produced by Fosfestrol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Anorexia, Diarrhea, Fever, Nausea and vomiting, Perineal pruritis, Perineal pain.

Fosfestrol is primarily indicated in conditions like Adjunct in the treatment of opiod dependence, Breast cancer, Dermatomyositis, Nasopharyngeal fibromas, Oncology, Parathyroid carcinoma, Plasmacytomas, Prostatic cancer, Rheumatoid arthritis.

No data regarding the interactions of Fosfestrol was found.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab, Inj Store Below 25°C.

High doses of estrogen used in treatment of malignant disease should be used cautiously in patients with cerebrovascular disorder, cardiovascular disease, coronary artery disease, venous thromboembolism or liver impairment. Estrogens should be used with caution in children, because premature closure of epiphysis may occur resulting in inhibited linear growth and small stature. Slow infusion is not recommended, because cytotoxic concentration of drug is not achieved. It is not recommended for use during pregnancy.